8-K
filed August 27, 2024, 7:59 PM ET
CIK 0001538210
other material
confidence high
sentiment negative
materiality 0.90
NexImmune appoints wind-down officer; all directors and execs resign after shareholder-approved dissolution
NexImmune, Inc.
- All eight directors, including CEO Kristi Jones, CSO Mathias Oelke, and interim CFO Albert Marchio, resigned effective Aug 27, 2024.
- Craig Jalbert appointed as sole director, President, Treasurer, Corporate Secretary, and principal executive/financial officer effective Aug 27.
- Jalbert to receive $50,000/year for three years for winding down the company.
- Board approved filing certificate of dissolution with Delaware Secretary of State upon completion of wind-down.
- Company cautions trading in NEXI stock is highly speculative; urges extreme caution.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kristi Jones resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig Jalbert was appointed as President at NexImmune, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
the Board also appointed Craig Jalbert, age 63, as the Company’s President, Treasurer and Corporate Secretary and as the Company’s principal executive officer, principal financial officer and principal accounting officer, effective as of August 27, 2024, and as the sole member of the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kristi Jones resigned as Chief Executive Officer at NexImmune, Inc..
- Action
- resigned
- Role
- Chief Executive Officer
Exact text from the filing
The resignations of Kristi Jones, the Company’s Chief Executive Officer, Mathias Oelke, the Company’s Chief Scientific Officer, and Albert N. Marchio II, the Company’s Interim Chief Financial Officer and its principal financial and accounting officer from the Company were not due to any disagreements with the Company on any matters relating to the Company’s operations, policies or practices.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Leena Gandhi resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sol J. Barer resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alan S. Roemer resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Grant Verstandig resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Zhengbin (Bing) Yao resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tim Bertram resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Albert N. Marchio II resigned as Interim Chief Financial Officer at NexImmune, Inc..
- Action
- resigned
- Role
- Interim Chief Financial Officer
Exact text from the filing
The resignations of Kristi Jones, the Company’s Chief Executive Officer, Mathias Oelke, the Company’s Chief Scientific Officer, and Albert N. Marchio II, the Company’s Interim Chief Financial Officer and its principal financial and accounting officer from the Company were not due to any disagreements with the Company on any matters relating to the Company’s operations, policies or practices.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Mathias Oelke resigned as Chief Scientific Officer at NexImmune, Inc..
- Action
- resigned
- Role
- Chief Scientific Officer
Exact text from the filing
The resignations of Kristi Jones, the Company’s Chief Executive Officer, Mathias Oelke, the Company’s Chief Scientific Officer, and Albert N. Marchio II, the Company’s Interim Chief Financial Officer and its principal financial and accounting officer from the Company were not due to any disagreements with the Company on any matters relating to the Company’s operations, policies or practices.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul D'Angio resigned as Director at NexImmune, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On August 21, 2024, Sol J. Barer, Kristi Jones, Alan S. Roemer, Tim Bertram, Paul D’Angio, Grant Verstandig, Zhengbin (Bing) Yao and Leena Gandhi, each notified the Company of their respective resignations as members of the Company’s Board of Directors (the “Board”), effective as of August 27, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.